Meet with our product experts in one-on-one virtual sessions
Set Up a Meeting
Apremilast (Amorphous & Form B)
Central Nervous System (CNS)
Atomoxetine Hydrochloride
Central Nervous System (CNS)
Benztropine Mesylate
Central Nervous System (CNS)
Dimethyl Fumarate
Central Nervous System (CNS)
Donepezil HCl
Central Nervous System (CNS)
Edaravone
Central Nervous System (CNS)
Eslicarbazepine Acetate
Central Nervous System (CNS)
Eszopiclone
Central Nervous System (CNS)
Levetiracetam
Central Nervous System (CNS)
Lumateperone Tosylate
Central Nervous System (CNS)
Lurasidone Hydrochloride
Central Nervous System (CNS)
Memantine Hydrochloride
Central Nervous System (CNS)
Pregabalin
Central Nervous System (CNS)
Quetiapine Fumarate
Central Nervous System (CNS)
Rimegepant
Central Nervous System (CNS)
Risperidone
Central Nervous System (CNS)
Rivastigmine Hydrogen Tartrate
Central Nervous System (CNS)
Ropinirole Hydrochloride
Central Nervous System (CNS)
Siponimod
Central Nervous System (CNS)
Sugammadex Sodium
Central Nervous System (CNS)
Tizanidine Hydrochloride
Central Nervous System (CNS)
Xanomeline
Central Nervous System (CNS)
Ziprasidone Hydrochloride
Central Nervous System (CNS)
USPs of our CNS APIs
- Firm PSD control to help maintain consistency of manufacturing process.
- Sufficient capacity to meet our customer’s global leadership requirements.
- Reliable KSM suppliers in India with timely deliveries and stringent specifications.
- IP compliant process.
- Well-controlled all the plausible impurities within the specified limit.
- Commercially available starting materials.
- Schemes of starting material evaluated.
- Flexible business models to support registrations.
- Adequate capacity available to supply development quantity in short lead time.
- Free from nitrosamine impurities.
- QBD (Quality by Design) based API development for consistent quality profile.
- Continuous improvement in place to achieve cost and quality excellence.
- Process safety and scalability.
- APIs suitable for global formulation development.
- Fully backward integration process.
- Compliant to all pharmacopeia’s.
- Multiple domestic sources for KSMs available.
- Able to match a wide range of particle size requirements.
Get access to Dr. Reddy's largest CNS API portfolios to support your formulation success
Dr. Reddy’s is one of the leading generic pharmaceutical companies and CNS API suppliers in the development and manufacturing of CNS APIs used in formulations to treat indications in the central nervous system (CNS) therapy area. Our CNS API product portfolio is broad-based, including APIs in the class of atypical antipsychotics, anticholinergics, Nrf2 activators, cholinesterase inhibitors, antioxidants, and GnRH antagonists.
Our CNS API product portfolio is broad-based, including APIs in the class of atypical antipsychotics, anticholinergics, Nrf2 activators, cholinesterase inhibitors, antioxidants, and GnRH antagonists.
They can act either as neurotransmitter agonists, such as the opioids, which mimic the action of enkephalin, or they can block receptor function. Receptor antagonism is a common mechanism of action for CNS drugs.
The global central nervous system therapeutic market was valued at 116.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.4% from 2021 to 2028. Advancements in diagnostics and therapeutics of CNS diseases are expected to increase the treatment rate globally.
Used to treat insomnia (trouble sleeping), anxiety, panic attacks, and seizures. They may also be used to relieve anxiety and tension before surgery. Examples of CNS depressants are benzodiazepines, barbiturates, and certain sleep medicines.
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.
Let’s talk API sourcing live at
Tackle sourcing bottlenecks and compliance hurdles